Virtual Symposium (Expired): Managing Inflammation: A Novel Approach for Secondary Prevention of CVD Risks

This educational activity is designed to update clinicians on the role of inflammation in the development and progression of atherosclerosis, the utilization of inflammatory biomarkers in assessing patients for secondary CVD risk, and the use of current and novel agents for the treatment of inflammation for secondary prevention of CVD risks. Expert faculty will engage in a roundtable discussion on these topics and present brief overviews on the pathogenesis of inflammation in atherosclerosis, the American College of Cardiology (ACC)/American Heart Association (AHA) 2013 guidelines and the National Lipid Association (NLA) Recommendations for the Patient-Centered Management of Dyslipidemia for the use of inflammatory biomarkers in patient assessment for secondary CVD risks, and evidence demonstrating the pleiotropic effects of statins and benefits and risks of current and novel agents for the treatment of inflammation in the prevention of secondary CVD risks. This activity is expected to bring more focus to the role of inflammation in the initiation and progression of atherosclerosis and as a treatment target for patients at risk.

Managing Inflammation: a Novel Approach for Secondary Prevention of CVD Risks

Faculty: Christie M. Ballantyne, MD

The Role of Inflammation in Atherosclerosis: Biology and Pathogenesis

Faculty: Peter Libby, MD

Inflammation as a Target for Therapy: Focus on "Residual Inflammatory Risk"

Faculty: Paul M. Ridker, MD

Audience Q&A

Presenter: All Faculty